With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.